Ceremonial Ayahuasca in Amazonian Retreats—Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Ayahuasca is a natural psychoactive brew, used in traditional ceremonies in the Amazon basin. Recent research has indicated that ayahuasca is pharmacologically safe and its use may be positively associated with improvements in psychiatric symptoms. The mechanistic effects of ayahuasca are yet to be fully established. In this prospective naturalistic study, 63 self-selected participants took part in ayahuasca ceremonies at a retreat centre in the Peruvian Amazon. Participants undertook the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Self-compassion Scale (SCS), Clinical Outcomes in Routine Evaluation-Outcome Measure (CORE-OM), as well as secondary measures, pre- and post-retreat and at 6-months. Participants also provided saliva samples for pre/post epigenetic analysis. Overall, a statistically significant decrease in BDI-II (13.9 vs. 6.1,p< 0.001), STAI (44.4 vs. 34.3 p< 0.001) scores, and CORE-OM scores were observed (37.3 vs. 22.3 p< 0.001) at post-retreat, as well as a concurrent increase in SCS (3.1 vs. 3.6,p< 0.001). Psychometric improvements were sustained, and on some measures values further decreased at 6-month follow-up, suggesting a potential for lasting therapeutic effects. Changes in memory valence were linked to the observed psychometric improvements. Epigenetic findings were equivocal, but indicated that further research in candidate genes, such as sigma non-opioid intracellular receptor 1 (SIGMAR1), is warranted. This data adds to the literature supporting ayahuasca's possible positive impact on mental health when conducted in a ceremonial context. Further investigation into clinical samples, as well as greater analyses into the mechanistic action of ayahuasca is advised.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Development and Validation of a Scale to Measure Self-Compassion
NEFF, K. D. (2003) · Self and Identity · doi:10.1080/15298860309027 · Cited by 6,436 · cited 1×
“Alongside a total score, it is comprised of six subscales, including three positive constructs of Self-Kindness, Common Humanity, Mindfulness, and their negative opposite constructs of Self-Judgement, Isolation, and Over-Identification (58).”
BackgroundInitial reliability and validity of a new retrospective measure of child abuse and neglect
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.8.1132 · Cited by 3,577
The default mode network and self-referential processes in depression
Sheline, Y. I., Barch, D. M., Price, J. L., Rundle, M. M., Vaishnavi, S. N., Snyder, A. Z., Mintun, M. A., Wang, S., Coalson, R. S., & Raichle, M. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812686106 · Cited by 1,480
Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., dos Santos, R. G., et al. (2019) · Psychological Medicine · doi:10.1017/s0033291718001356 · Cited by 852
Self-citationHamilton, J. P., Furman, D. J., Chang, C., Thomason, M. E., Dennis, E., & Gotlib, I. H. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.02.003 · Cited by 823
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739 · cited 1×
“…been likened to that of intense psychotherapy (36), with a number of authors suggesting it as a treatment candidate for trauma and related disorders (37–39), potentially via reprocessing of autobiographic and emotional memories which can be elicited with the ayahuasca-induced dream-like state (17).”
BackgroundGene–Stress–Epigenetic regulation of FKBP5: clinical and translational implications
Zannas, A. S., Wiechmann, T., Gassen, N. C., & Binder, E. B. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.235 · Cited by 622
CORE: Clinical Outcomes in Routine Evaluation
Evans, C., Mellor-Clark, J., Margison, F., Barkham, M., Audin, K., Connell, J., & McGrath, G. (2000) · Journal of Mental Health · doi:10.1080/713680250 · Cited by 560 · cited 1×
“The CORE-OM is a widely used initial screening and monitoring clinical tool with high internal and test-retest reliability (59).”
MethodThe Hallucinogen N,N -Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator
Fontanilla, D., Johannessen, M., Hajipour, A. R., Cozzi, N. V., Jackson, M. B., & Ruoho, A. E. (2009) · Science · doi:10.1126/science.1166127 · Cited by 535 · cited 1×
“Agonism of these receptors have been associated with antidepressive and anxiolytic effects (11, 12).”
BackgroundConstructing drug effects: a history of set and setting
Hartogsohn, I. (2017) · Drug Science Policy and Law · doi:10.1177/2050324516683325 · Cited by 472 · cited 1×
“Without a supportive “set and setting” (75), ayahuasca experiences may not produce benefit, and could even be traumatic (74, 76).”
BackgroundSanches, R. F., de Lima Osório, F., dos Santos, R. G., Macedo, L. R. H., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000436 · Cited by 466 · cited 1×
“For the purposes of this study, we used the following cut-off points as recommended by the authors of the BDI-II: “not depressed” (0– 13), “mild depression” (14–19), “moderate depression” (20–28), “severe depression” (29–63) (56).”
Palhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118143 · Cited by 454
Predicting responses to psychedelics: a prospective study
Haijen, E. C. H. M., Kaelen, M., Roseman, L., Timmermann, C., Kettner, H., Russ, S., Nutt, D., Daws, R. E., Hampshire, A. D. G., Lorenz, R., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00897 · Cited by 417
Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., & Barbanoj, M. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049882 · Cited by 390
Finding the self by losing the self: neural correlates of ego-dissolution under psilocybin
Lebedev, A. V., Lövdén, M., Rosenthal, G., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2015) · Human Brain Mapping · doi:10.1002/hbm.22833 · Cited by 339 · cited 1×
“Measures of subjective mystical experiences were also recorded (33, 51).”
MethodThe therapeutic potentials of Ayahuasca: possible effects against various diseases of civilization
Frecska, E., Bokor, P., & Winkelman, M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00035 · Cited by 242 · cited 2×
“Ayahuasca experiences have been likened to that of intense psychotherapy (36), with a number of authors suggesting it as a treatment candidate for trauma and related disorders (37–39), potentially via reprocessing of autobiographic and emotional memories which can be elicited with the ayahuascainduced dream-like state…”
BackgroundSeeing with the eyes shut: neural basis of enhanced imagery following ayahuasca ingestion.
de Araujo, D. B., Ribeiro, S., Cecchi, G. A., Carvalho, F. M., Sanchez, T. A., Pinto, J. P., de Martinis, B. S., Crippa, J. A., Hallak, J. E. C., & Santos, A. C. (2012) · Human Brain Mapping · doi:10.1002/hbm.21381 · Cited by 239
The antipodes Of the mind: Charting the Phenomenology of the Ayahuasca Experience
Shanon, B. (2002) · doi:10.1093/oso/9780199252923.001.0001 · Cited by 232
Assessment of addiction severity among ritual users of ayahuasca.
Fábregas, J. M., González, D., Fondevila, S., Cutchet, M., Fernández, X., Barbosa, P. C. R., Alcázar-Córcoles, M. Á., Barbanoj, M. J., Riba, J., & Bouso, J. C. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.03.024 · Cited by 227 · cited 1×
“Ayahuasca is safe when used with due caution (23) and has a low dose tolerance and addictive potential (24).”
BackgroundAyahuasca: pharmacology, neuroscience and therapeutic potential
Domínguez-Clavé, E., Soler, J., Elices, M., Pascual, J. C., Álvarez, E., de la Fuente Revenga, M., Friedlander, P., Feilding, A., & Riba, J. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.03.002 · Cited by 226
Uthaug, M. V., van Oorsouw, K., Kuypers, K. P. C., van Boxtel, M., Broers, N. J., Mason, N. L., Toennes, S. W., Riba, J., & Ramaekers, J. G. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4988-3 · Cited by 212
Soler, J., Elices, M., Franquesa, A., Barker, S., Friedlander, P., Feilding, A., Pascual, J. C., & Riba, J. (2016) · Psychopharmacology · doi:10.1007/s00213-015-4162-0 · Cited by 209
Barbosa, P. C. R., Giglio, J. S., & Dalgalarrondo, P. (2005) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2005.10399801 · Cited by 120
Ayahuasca in Adolescence: A Preliminary Psychiatric Assessment
Da Silveira, D. X., Grob, C. S., de Rios, M. D., Lopez, E., Alonso, L. K., Tacla, C., & Doering-Silveira, E. (2005) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2005.10399792 · Cited by 113
Uthaug, M. V., Mason, N. L., Toennes, S. W., Reckweg, J. T., de Sousa Fernandes Perna, E. B., Kuypers, K. P. C., van Oorsouw, K., Riba, J., & Ramaekers, J. G. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05817-8 · Cited by 112
Kavenská, V., & Simonová, H. (2015) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2015.1094590 · Cited by 108
Bishop, J. R., Lee, A. M., Mills, L. J., Thuras, P. D., Eum, S., Clancy, D., Erbes, C. R., Polusny, M. A., Lamberty, G. J., & Lim, K. O. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00418 · Cited by 98 · cited 3×
“4.8%), and five PTSD (4.8%).”
BackgroundInfluentialSet and setting: a randomized study of different musical genres in supporting psychedelic therapy
Strickland, J. C., Garcia-Romeu, A., & Johnson, M. W. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00187 · Cited by 97
Inserra, A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00330 · Cited by 91 · cited 2×
“Coupled with previous evidence for the marker’s role in trauma (42, 43), the correlation (albeit weak) between childhood trauma and changes in SIGMAR1 methylation, alongside the improvements in mental health outcomes observed in our present sample, we propose that future research should investigate SIGMAR1 as a potent…”
BackgroundResultSelf-citationTherapeutic potential of ayahuasca in grief: a prospective, observational study
González, D., Cantillo, J., Pérez, I., Farré, M., Feilding, A., Obiols, J. E., & Bouso, J. C. (2020) · Psychopharmacology · doi:10.1007/s00213-019-05446-2 · Cited by 75
The Shipibo ceremonial use of ayahuasca to promote well-being: An observational study
Gonzalez, D., Cantillo, J., Perez, I., Carvalho, M., Aronovich, A., Farre, M., Feilding, A., Obiols, J. E., & Bouso, J. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.623923 · Cited by 40
Wolff, T. J., Ruffell, S., Netzband, N., & Passie, T. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.007 · Cited by 40 · cited 2×
“Visual phenomena are also often reported, ranging from colourful geometric patterns to vivid dream-like experiences, alongside transient dissociation, enhanced introspection and initial anxiety followed by euthymia (9, 15, 18–20).”
Background
Cited by
van Oorsouw, K., Toennes, S. W., & Ramaekers, J. G. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06046-9 · Cited by 74
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
“The clinical relevance of putative epigenetic changes in humans are not yet clear (129).”
BackgroundEpigenetic Mechanisms of Rapid-Acting Antidepressants
Inserra, A., Campanale, A., Rezai, T., Romualdi, P., & Rubino, T. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03055-y · Cited by 27
“These changes were accompanied by improved depression and anxiety scores for up to 6 months [79].”
BackgroundInfluentialSelf-citation
Metadata
- Authors
- Ruffell, S. G. D., Netzband, N., Tsang, W., Davies, M., Inserra, A., Butler, M., Rucker, J. J. H., Tófoli, L. F., Dempster, E. L., Young, A. H., & Morgan, C. J. A.
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2021-06-09
- Volume
- 12
- Pages
- 687615-687615
- ISSN
- 1664-0640 (ISSN-L)
- OpenAlex
- W3166424032
- Cited by
- 74
- References
- 34
- FWCI
- 6.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.